Duke Clinical Research Institute, Durham, North Carolina. Electronic address: https://twitter.com/G_MarquisGravel.
Duke Clinical Research Institute, Durham, North Carolina.
J Am Coll Cardiol. 2020 Jul 14;76(2):162-171. doi: 10.1016/j.jacc.2020.05.031.
The long-term prognostic impact of post-discharge bleeding in the unique population of patients with acute coronary syndrome (ACS) treated without percutaneous coronary intervention (PCI) remains unexplored.
The aim of this study was to assess the association between post-discharge bleeding and subsequent mortality after ACS according to index strategy (PCI or no PCI) and to contrast with the association between post-discharge myocardial infarction (MI) and subsequent mortality.
In a harmonized dataset of 4 multicenter randomized trials (APPRAISE-2 [Apixaban for Prevention of Acute Ischemic Events-2], PLATO [Study of Platelet Inhibition and Patient Outcomes], TRACER [Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome], and TRILOGY ACS [Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes]), the association between post-discharge noncoronary artery bypass graft-related GUSTO (Global Use of Strategies to Open Occluded Coronary Arteries) moderate, severe, or life-threatening bleeding (landmark 7 days post-ACS) and subsequent all-cause mortality was evaluated in a time-updated Cox proportional hazards analysis. Interaction with index treatment strategy was assessed. Results were contrasted with risk for mortality following post-discharge MI.
Among 45,011 participants, 1,133 experienced post-discharge bleeding events (2.6 per 100 patient-years), and 2,149 died during follow-up. The risk for mortality was significantly higher <30 days (adjusted hazard ratio: 15.7; 95% confidence interval: 12.3 to 20.0) and 30 days to 12 months (adjusted hazard ratio: 2.7; 95% confidence interval: 2.1 to 3.4) after bleeding, and this association was consistent in participants treated with or without PCI for their index ACS (p for interaction = 0.240). The time-related association between post-discharge bleeding and mortality was similar to the association between MI and subsequent mortality in participants treated with and without PCI (p for interaction = 0.696).
Post-discharge bleeding after ACS is associated with a similar increase in subsequent all-cause mortality in participants treated with or without PCI and has an equivalent prognostic impact as post-discharge MI.
在未接受经皮冠状动脉介入治疗(PCI)的急性冠状动脉综合征(ACS)患者这一独特人群中,出院后出血对长期预后的影响仍不清楚。
本研究旨在评估根据索引策略(PCI 或无 PCI)评估 ACS 后出院后出血与随后死亡率之间的关联,并与出院后心肌梗死(MI)与随后死亡率之间的关联进行对比。
在 4 项多中心随机试验(APPRAISE-2[Apixaban 预防急性缺血性事件-2]、PLATO[血小板抑制和患者结局研究]、TRACER[凝血酶受体拮抗剂在急性冠状动脉综合征中的临床事件减少]和 TRILOGY ACS[血小板抑制以明确急性冠状动脉综合征的最佳药物管理策略])的协调数据集内,采用时间更新 Cox 比例风险分析评估出院后非冠状动脉旁路移植术相关 GUSTO(全球使用策略以开通闭塞冠状动脉)中度、重度或危及生命的出血(ACS 后 7 天里程碑)与随后全因死亡率之间的关系。评估了与索引治疗策略的相互作用。将结果与 MI 后死亡率的风险进行了对比。
在 45011 名参与者中,有 1133 人发生了出院后出血事件(每 100 患者年 2.6 例),在随访期间有 2149 人死亡。出血后 30 天内(校正风险比:15.7;95%置信区间:12.3 至 20.0)和 30 天至 12 个月(校正风险比:2.7;95%置信区间:2.1 至 3.4)死亡风险显著升高,且该相关性在接受或不接受 PCI 治疗其索引 ACS 的参与者中一致(p 交互作用=0.240)。出院后出血与死亡率之间的时间相关性与接受或不接受 PCI 治疗的参与者中 MI 与随后死亡率之间的相关性相似(p 交互作用=0.696)。
ACS 后出院后出血与接受或不接受 PCI 治疗的患者随后全因死亡率的增加相似,具有同等的预后影响,与出院后 MI 相当。